Stevanato Group to Participate in Upcoming Investor Conferences
Stevanato Group S.p.A. Reports Third Quarter 2026 Financial Results and Outlines 2027 Outlook
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
Stevanato Group S.p.A. Consensus Price Target Decreased by 21.06% to $20.22
William Blair Downgrades Stevanato Group S.p.A. to Market Perform from Outperform
Why Stevanato Group Bears Were Right Before The Drop
William Blair Downgrades Stevanato Group to Market Perform
UBS Maintains Neutral on Stevanato Group, Lowers Price Target to $16
Citigroup Maintains Buy on Stevanato Group, Lowers Price Target to $20
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
Stevanato Group Q3 Earnings Call Highlights
Stevanato Group S.p.A. Reports Revenue of EUR 326.1 Million for the Three Months Ended September 30, 2026
Stevanato Group S.p.A. Q3 2026 Earnings Call Summary
Stevanato Group S.p.A. Reports Q3 2026 Revenue of 326 Million Euros
Stevanato Group S.p.A. Reports 8% Revenue Growth for the Third Quarter of Fiscal 2026
Stevanato (STVN) Q3 2026 Earnings Call Transcript
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
Stevanato Group S.p.A. (STVN) Q3 2026 Earnings Call Transcript
Stevanato: Q3 Earnings Snapshot
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.